In conclusion, this study emphasizes the significance of EPHB1-GSK3B-SMAD3 signaling in PRAD progression and provides a new theoretical basis and experimental support for future studies on the molecular mechanism of PRAD and the development of clinical treatment strategies for cancer. This evidence concerns the gene EPHB1 and prostate adenocarcinoma.